@FiercePharma: U.S. FDA Form 483 has Indian drugmakers 'spooked'. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: If the quarterly Vivus trend keeps up, I'm pretty sure that we're about to find out they have zero remaining sales reps | Follow @CarlyHFierce
> Celgene ($CELG) posted a double-digit sales increase for Q3, despite declining sales of its cancer drug Abraxane, but earnings fell on acquisition costs. Release
> AstraZeneca ($AZN) and Teva Pharmaceutical Industries' ($TEVA) Cephalon unit agreed to pay a group of states $54 million to settle Medicaid price-reporting allegations; the drugmakers wrapped up similar allegations with the U.S. Justice Department earlier this year. Report
> The Indian generics maker Cipla saw net profits grow by 44% for its latest quarter, but that 4.31 billion rupee profit still lagged analyst estimates, thanks to increased expenses. Report
Medical Device News
@FierceMedDev:Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. Read more | Follow @FierceMedDev
@VarunSaxena2: Investigational drug enables faster absorption of bioresorbable drug-eluting stents. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: Biosensors sells out to Chinese private equity firm for $787M. Story | Follow @EmilyWFierce
> Allergan beefs up in aesthetics with implant purchase. Does M&A suitor Pfizer approve? Report
> Boston Scientific files patent infringement suit against Edwards' Sapien 3 TAVR. Story
> FDA adds another artificial kidney to its Expedited Access Pathway program. News
Biotech News
@FierceBiotech: GSK, Gates Foundation help immuno-oncology player to $56M Series A round. Story | Follow @FierceBiotech
@JohnCFierce: Relentless masochism... NYT story | Follow @JohnCFierce
> Bluebird slips as new data paints a cloudy picture for its gene therapy. Report
> Sanofi inks a $4.2B diabetes deal, playing pipeline catch-up with Novo and Lilly. Story
> FierceBiotech Radio on the latest Valeant drama, Pfizergan and Shire's latest buyout. Listen online
CRO News
> Icon eyes Asia growth with a pair of exec appointments. More
> Catalent ekes out revenue growth in the face of currency troubles. News
> PRA narrows its sales guidance on the way to a record year. Story
> Charles River boosts its 2015 outlook after strong sales quarter. Article
> WuXi pads its revenue on the way to a big buyout decision. More
Pharma Manufacturing News
> Turing again vows to cut drug's cost as compounder starts manufacturing a version. Story
> India's Torrent Pharma targets production from new plant at U.S., EU. More
> Pfizer will transfer manufacturing tech for Prevenar 13. News
> Novo starts in on massive production buildup. Article
> Novartis, others face higher manufacturing costs with CAR-T cell treatments. More
Pharma Asia News
> Indian drugmakers on the hunt for money and growth. More
> Australia looks to save cash by cutting scripts for common drugs. News
> Generic drugs cut costs by $254B in U.S. last year. Story
> AbbVie nears launch of Viekira into crowded Japan HCV battle. Article
> Roche gets temporary court injunction on Herceptin biosimilar in India. News
And Finally... The Generic Pharmaceutical Association (GPhA) said the U.S. healthcare system saved $254 billion last year by using lower-cost generics instead of branded meds. Report